Skip to main content


RGX-314 is a potential one-time gene therapy being investigated for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

Type of Molecule

Gene Therapy



Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Wet Age-related Macular Degeneration (wet AMD) n/a
Phase 3
Diabetic Retinopathy n/a
Phase 2